QUEBEC CITY, Aug. 5 /CNW/ - Medicago Inc. (TSX-V: MDG) today announced
that its President and CEO, Mr. Andy Sheldon, is a member of the delegation
that will represent the province of Québec at the 4th Conference of Heads of
Government of Partner Regions, being held in Jinan, China from August 5-8,
2008. Led by Mr. Jean Charest, the Premier of Québec, and Ms. Monique
Gagnon-Tremblay, International Relations Minister, the Quebec delegation will
consist of six Quebec-based companies, including Medicago as the only life
sciences company. Mr. Sheldon will meet with health officials of the province
of Shandong to present Medicago's proprietary plant-based vaccine development
and production technologies and how the Company is able to address pandemic
planning in the most efficient and effective manner.
"Ongoing outbreaks of H5N1 Avian Influenza in Asia pose a significant
risk for a pandemic emphasizing the importance of preparedness in this region
of the world," said Andy Sheldon, President and CEO of Medicago. "We believe
our plant-based vaccine manufacturing technology can help China prepare for
future outbreaks of H5N1 and prevent or reduce the impact of a pandemic."
During the conference, the Heads of Government of Upper Austria, Bavaria,
Western Cape, Georgia, Shandong, Sao Paulo, and Québec will gather to discuss
the development of action plans to promote the adoption of government policies
that reconcile economic development, social protection, the sustainable
preservation of resources essential for life and the promotion of cultural
diversity for future generations. The theme for this year's conference will be
"Health and Medical Care" and "Building a Resource-Conserving Society".
Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at www.medicago.com.
This press release contains forward-looking statements which reflect
Medicago's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. Medicago disclaims any obligation to
update these forward-looking statements.
The TSX Venture Exchange assumes no responsibility for the content or
accuracy of this press release
For further information:
For further information: Medicago, Inc., Andy Sheldon, President and
CEO, (418) 658-9393; Investor relations: The Equicom Group Inc., Arianna
Vanin, (514) 844-4680, email@example.com